Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Menopause
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Menopause
    TopAbstracts in Menopause 06/24/2008 - (DGNews)
    Teriparatide Tops Alendronate in Multiple Subgroups at Increased Fracture Risk: Presented at EULAR - (DGDispatch)
    TopAbstracts in Menopause 06/10/2008 - (DGNews)
    TopAbstracts in Menopause 05/27/2008 - (DGNews)
    Oral Hormone Replacement Therapy May Double Risk of Blood Clots in Women - (DGNews)

    News archive

     Recent webcasts/CME - Menopause
    • Incorporating Aromatase Inhibitors Into Adjuvant Therapy for Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer
    • Management of Vasomotor Symptoms During the Menopausal Transition
      When is Postmenopausal Hormone Therapy Indicated Now?
      Uses of Progesterone Throughout a Woman's Life
      Female Sexual Desire and Aging

      Webcasts/CME archive

       Recent cases - Menopause
        Uterine Leiomyomas with Tubules
        Tubercular Mastitis Masquerading as Carcinoma: A Case Report
        LV Apical Ballooning Syndrome--Takotsubo Cardiomyopathy
        A Case of Non-Metastatic Giant Mucinous Carcinoma of the Breast
        Genital Tuberculosis in a Tamoxifen-Treated Postmenopausal Woman with Breast Cancer and Bloody Vaginal Discharge

        Cases archive
          




        my personal edition > menopause > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Hormone Therapy Plus Alendronate Better for Bone Density than Hormone Therapy Alone: Presented at NAMS

        By W. A. Thomasson
        Special to DG News

        CHICAGO, IL -- October 8, 2002 -- Either oral or transdermal estrogen-progestin therapy improves bone mineral density in postmenopausal women, but the improvement is greater when alendronate is added to the therapy.

        This was the conclusion of a study presented Friday at the annual meeting of the North American Menopause Society by Ahmet Varolan, MD, and colleagues at Sisli Etfal Training and Research Hospital in Istanbul, Turkey.

        The study enrolled 173 women (13 unevaluable due to noncompliance) who had climacteric complaints, were at least one year past the last menses, and had a vertebral bone mineral T-score of -1 or lower.

        All patients received oral medroxyprogesterone acetate 5 mg/day -- half received conjugated estrogens 0.625 mg/day orally, the other half 0.05 mg of transdermal estrogen twice a week. Half the patients in each group also received alendronate 10 mg/day. Results were analyzed separately for women who were osteopenic (-2.5 < T-score < -1) and those who were osteoporotic (T-score < -2.5). Results were also analyzed separately for osteopenic women with T-score < -1.5 and those with -1.5 < T-score < -1.

        Bone mineral density was re-evaluated at the end of one year of treatment. An increase was found in all treatment groups, regardless of initial T-scores, although the increase was greater in women with initially lower bone density. The extent of the increase did not vary significantly with the type of estrogen treatment. In all cases, however, the increase was significantly greater in patients who received alendronate than in those who did not.

        Thus, the authors concluded, although hormone therapy alone is clearly beneficial in osteopenic or osteoporotic postmenopausal women, combined hormone and alendronate therapy is the preferred choice.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send